BIOMAT Database Logo BIOMAT Database Logo

[Indomethacin and a tocolytic agent: fetal and neonatal outcome]. 1990

R Shamir, and A Litwin, and A Merlob

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007752 Obstetric Labor, Premature Onset of OBSTETRIC LABOR before term (TERM BIRTH) but usually after the FETUS has become viable. In humans, it occurs sometime during the 29th through 38th week of PREGNANCY. TOCOLYSIS inhibits premature labor and can prevent the BIRTH of premature infants (INFANT, PREMATURE). Preterm Labor,Labor, Premature,Premature Labor,Premature Obstetric Labor,Labor, Premature Obstetric,Labor, Preterm
D008297 Male Males
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011297 Prenatal Exposure Delayed Effects The consequences of exposing the FETUS in utero to certain factors, such as NUTRITION PHYSIOLOGICAL PHENOMENA; PHYSIOLOGICAL STRESS; DRUGS; RADIATION; and other physical or chemical factors. These consequences are observed later in the offspring after BIRTH. Delayed Effects, Prenatal Exposure,Late Effects, Prenatal Exposure
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R Shamir, and A Litwin, and A Merlob
Fetal and neonatal effects of indomethacin used as a tocolytic agent.
January 1985, American journal of obstetrics and gynecology,
R Shamir, and A Litwin, and A Merlob
Fetal and neonatal effects of indomethacin used as a tocolytic agent.
November 1985, American journal of obstetrics and gynecology,
R Shamir, and A Litwin, and A Merlob
Fetal and neonatal effects of indomethacin used as a tocolytic agent.
December 1985, American journal of obstetrics and gynecology,
R Shamir, and A Litwin, and A Merlob
Prenatal administration of indomethacin as a tocolytic agent: effect on neonatal renal function.
October 1990, Obstetrics and gynecology,
R Shamir, and A Litwin, and A Merlob
Indomethacin as a tocolytic agent: the controversy continues.
May 1994, The Journal of pediatrics,
R Shamir, and A Litwin, and A Merlob
Can a cyclo-oxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin?
March 2001, BJOG : an international journal of obstetrics and gynaecology,
R Shamir, and A Litwin, and A Merlob
Tocolytic indomethacin: effects on neonatal haemodynamics and cerebral autoregulation in the preterm newborn.
September 2013, Archives of disease in childhood. Fetal and neonatal edition,
R Shamir, and A Litwin, and A Merlob
The relationship between antenatal indomethacin as a tocolytic drug and neonatal outcomes: a retrospective cohort study.
September 2021, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians,
R Shamir, and A Litwin, and A Merlob
Outcome of vaginal progesterone as a tocolytic agent: randomized clinical trial.
January 2012, ISRN obstetrics and gynecology,
R Shamir, and A Litwin, and A Merlob
A Potentially New Tocolytic Agent.
November 2018, Reproductive sciences (Thousand Oaks, Calif.),
Copied contents to your clipboard!